Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrx once-daily fexofenadine under development with Sepracor -- SEC registration.

Executive Summary

ANDRX ONCE-DAILY FEXOFENADINE WILL BE FIRST BRANDED PRODUCT, the company indicates in a recent registration statement filed with the Securities & Exchange Commission. Under an April 1996 agreement with Sepracor, Andrx will develop a once-daily formulation of fexofenadine (terfenadine carboxylate) and will receive fees and royalties from eventual sales or licensing of the antihistamine. Under the agreement, Sepracor has responsibility for obtaining FDA approval, manufacturing and marketing the once-daily fexofenadine.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029747

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel